









Markets
/
Stocks
/
nasdaq-janx
/

Janux Therapeutics Inc

JANX

23.983USD

+0.523+2.23%

Market hours （ET）Quotes delayed by 15 min

1.42BMarket Cap

LossP/E TTM



Janux Therapeutics Inc

23.983

+0.523+2.23%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

83 / 507

Overall Ranking

196 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 17 analysts

Buy

Current Rating

78.400

Target Price

+234.90%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22.94% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.59M.

Fairly Valued

The company’s latest PE is -12.96, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 71.98M shares, decreasing 5.69% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.18M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 5.54, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 468.18%.

Score

Industry at a Glance

Previous score

5.54

Change



Financials

2.15

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.18

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.73

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.50

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.14

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -12.96, which is -33.15% below the recent high of -8.66 and -132.32% above the recent low of -30.10.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 83/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.82, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Janux Therapeutics Inc is 72.00, with a high of 200.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

8.82

Change

Support & Resistance

No Data

Analyst Rating

Based on 17 analysts

Buy

Current Rating

78.400

Target Price

+234.19%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Janux Therapeutics Inc

JANX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.59, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 25.23 and the support level at 22.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.48

Change

0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.018

Neutral

RSI(14)

46.185

Neutral

STOCH(KDJ)(9,3,3)

23.399

Sell

ATR(14)

1.182

High Vlolatility

CCI(14)

5.847

Neutral

Williams %R

66.981

Sell

TRIX(12,20)

-0.063

Sell

StochRSI(14)

3.352

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

23.920

Buy

MA10

24.042

Sell

MA20

23.763

Buy

MA50

24.564

Sell

MA100

25.041

Sell

MA200

32.808

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 121.61%, representing a quarter-over-quarter decrease of 2.14%. The largest institutional shareholder is The Vanguard, holding a total of 2.18M shares, representing 3.63% of shares outstanding, with 1.66% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

11.19M

+0.03%

Fidelity Management & Research Company LLC

8.59M

+0.33%

Janus Henderson Investors

4.60M

+29.07%

Bregua Corp

3.00M

-21.68%

Paradigm BioCapital Advisors LP

3.33M

-5.29%

BlackRock Institutional Trust Company, N.A.

2.52M

+4.85%

Adage Capital Management, L.P.

3.65M

+19.36%

The Vanguard Group, Inc.

Star Investors

2.27M

+6.69%

T. Rowe Price Associates, Inc.

Star Investors

1.36M

+25.31%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.12, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.83. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.